{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:09:41Z","timestamp":1780319381075,"version":"3.54.1"},"reference-count":50,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Prostate cancer (PCa) is biologically heterogeneous, requiring management strategies that balance oncologic benefit with preservation of quality of life. Prostate-specific membrane antigen (PSMA) has emerged as a key theranostic biomarker enabling highly sensitive molecular imaging and targeted therapy. Purpose: The present manuscript aims to summarize the clinical role of PSMA-PET\/CT in PCa across staging, treatment selection, and response assessment, with a special focus on its contribution to personalized management. Key Findings: PSMA-PET\/CT demonstrates superior accuracy compared with conventional imaging, frequently leading to stage migration and changes in therapeutic strategy. It improves detection of metastatic and recurrent disease, guides selection for systemic and PSMA-targeted therapies, and supports metastasis-directed treatment in oligometastatic settings, potentially delaying androgen-deprivation therapy and preserving quality of life. Additionally, PSMA-PET enhances intra-prostatic lesion delineation for focal therapies and radiotherapy planning. Limitations include reduced sensitivity for very small lesions, possible false positives, variability among tracers, and issues related to access and standardization. Conclusions: PSMA-PET\/CT is a cornerstone of precision imaging in PCa, enabling more individualized treatment decisions across the disease continuum. Ongoing studies will further define its long-term clinical impact and integration into routine care.<\/jats:p>","DOI":"10.3390\/cancers18111799","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:19:42Z","timestamp":1780316382000},"page":"1799","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Cesare","family":"Guida","sequence":"first","affiliation":[{"name":"Radiotherapy Complex Unit, Ospedale del Mare, Azienda Sanitaria Locale Napoli 1 Centro, 80147 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-9488","authenticated-orcid":false,"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6586-4577","authenticated-orcid":false,"given":"Marco","family":"Spadafora","sequence":"additional","affiliation":[{"name":"Medicina Futura, 80143 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-001X","authenticated-orcid":false,"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[{"name":"Oncology Complex Unit, Santa Maria delle Grazie Hospital, Azienda Sanitaria Locale Napoli 2 Nord, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-5134","authenticated-orcid":false,"given":"Luigi","family":"Mansi","sequence":"additional","affiliation":[{"name":"Interuniversity Research Center for Sustainability (CIRPS), 00038 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/10408363.2024.2322565","article-title":"Implication of calcium supplementations in health and diseases with special focus on colorectal cancer","volume":"61","author":"Khan","year":"2024","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_3","first-page":"759","article-title":"Calcium supplementation in colorectal cancer prevention: A systematic meta-analysis of adverse events","volume":"46","author":"Luo","year":"2021","journal-title":"Biocell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189229","DOI":"10.1016\/j.bbcan.2024.189229","article-title":"Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer","volume":"1880","author":"Khan","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s12672-025-03875-4","article-title":"Assessing the efficacy of darolutamide in metastatic hormone-sensitive prostate cancer based on subgroup meta-analysis and reconstructed individual patient data","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40336-023-00582-4","article-title":"PSMA PET\/CT and PET\/MRI in primary staging of prostate cancer and its effect on patient management","volume":"12","author":"Claes","year":"2023","journal-title":"Clin. Transl. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014A systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00259-025-07507-5","article-title":"PSMA-Targeted radiopharmaceuticals: From diagnosis to risk & quality of life","volume":"53","author":"Evangelista","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1464-410X.2010.09652.x","article-title":"Watchful waiting for localized prostate cancer in the PSA era: What have been the triggers for intervention?","volume":"107","author":"Coen","year":"2011","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrurol.2015.313","article-title":"Active surveillance for prostate cancer: A narrative review of clinical guidelines","volume":"13","author":"Bruinsma","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/CCO.0000000000000827","article-title":"Active surveillance in favorable intermediate risk prostate cancer: Outstanding questions and controversies","volume":"34","author":"Russell","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/21681805.2016.1194460","article-title":"Long-term adverse effects after curative radiotherapy and radical prostatectomy: Population-based nationwide register study","volume":"50","author":"Fridriksson","year":"2016","journal-title":"Scand. J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0970-1591.52907","article-title":"Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues","volume":"25","author":"Bagrodia","year":"2009","journal-title":"Indian. J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40336-025-00716-w","article-title":"Impact of tumor burden on physiological organ biodistribution in 18F-PSMA PET\/CT of patients with prostate cancer","volume":"13","author":"Ahmed","year":"2025","journal-title":"Clin. Transl. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s00259-025-07083-8","article-title":"The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer","volume":"52","author":"Laudicella","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1007\/s00259-025-07292-1","article-title":"PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels \u2264 0.2 ng\/mL: A German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]FPSMA-1007","volume":"52","author":"Burgard","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.euf.2024.11.006","article-title":"Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography-guided Salvage Radiotherapy Following Prostatectomy","volume":"11","author":"Zamboglou","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","article-title":"Equivocal bone lesions on PSMA PET\/CT: Systematic review and meta-analysis on their prevalence and malignancy rate","volume":"12","author":"Woo","year":"2024","journal-title":"Clin. Transl. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cpet.2025.01.001","article-title":"Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer","volume":"20","author":"Wang","year":"2025","journal-title":"PET Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2967\/jnumed.124.268441","article-title":"Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET\u2014An International Multicenter Retrospective Study","volume":"66","author":"Unterrainer","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_24","first-page":"S526","article-title":"Assessing the Supplementary Role of PSMA PET Parameters in Metastatic Hormone-Sensitive Prostate Cancer Patients Initiating First-Line Therapy; Abstract EANM24","volume":"51","author":"Zanca","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Droghetti, M., Bianchi, L., Presutti, M., Vetrone, L., Farolfi, A., Mei, R., Giunchi, F., Degiovanni, A., Mottaran, A., and Piazza, P. (2024). Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: Potential implications for PSMA-PET patient selection. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1324631"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic Performance of 18F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2025.12.003","article-title":"[18F]F-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial","volume":"89","author":"Jani","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2967\/jnumed.121.263684","article-title":"The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging","volume":"63","author":"Sutera","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1200\/JCO.2023.41.6_suppl.315","article-title":"Detection of true positive M1 lesions by 18 F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study","volume":"41","author":"Koontz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A Phase 2\/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET\/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.2020.38.6_suppl.93","article-title":"Oligopelvis-GETUG P07: A multicenter phase II trial of combined salvage radiotherapy and hormone therapy in oligorecurrent plevic node relpases of prostate cancer","volume":"38","author":"Supiot","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijrobp.2025.04.039","article-title":"PSMA MRI Guided prOstate SBRT (ARGOS)\/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I\/II Trial","volume":"123","author":"Ramadan","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_37","first-page":"S534","article-title":"The Power Duo: PSMA PET\/CT and Focal Ablation in Prostate Cancer (PCa) Care","volume":"1","author":"Jandric","year":"2025","journal-title":"EANM Innov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s13063-021-05733-4","article-title":"Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: The BULLSEYE trial","volume":"22","author":"Janssen","year":"2021","journal-title":"Trials"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijrobp.2025.03.033","article-title":"PSMA-PET Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial","volume":"125","author":"Singh","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2967\/jnumed.122.265025","article-title":"68Ga-PSMA PET\/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines","volume":"64","author":"Sonni","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-025-07317-9","article-title":"Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany","volume":"52","author":"Brinkmann","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11307-023-01841-6","article-title":"PI-RADS-Based Segmented Threshold of PSMA-PET SUVmax Is Better than Traditional Fixed Threshold for Diagnosing Clinically Significant Prostate Cancer Especially for PI-RADS 3 Lesions","volume":"25","author":"Meng","year":"2023","journal-title":"Mol. Imaging Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis","volume":"89","author":"Herrmann","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1159\/000526598","article-title":"The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey","volume":"106","author":"Borkowetz","year":"2022","journal-title":"Urol. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40336-025-00740-w","article-title":"Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: Technical aspects and primary staging setting","volume":"14","author":"Bauckneht","year":"2025","journal-title":"Clin. Transl. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/ajco.13722","article-title":"Managing advanced prostate cancer in the Asia Pacific region: \u201cReal-world\u201d application of Advanced Prostate Cancer Consensus Conference 2019 statements","volume":"18","author":"Chiong","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"M\u00e9nard, C., Young, S., Zukotynski, K., Hamilton, R.J., B\u00e9nard, F., Yip, S., McCabe, C., Saad, F., Brundage, M., and Nitulescu, R. (2022). PSMA PET\/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): A pragmatic phase III randomized controlled trial. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09283-z"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.euo.2025.08.005","article-title":"Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2\/3 THUNDER Trial","volume":"8","author":"Kleiburg","year":"2025","journal-title":"Eur. Urol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1799\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:37:41Z","timestamp":1780317461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111799"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111799","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}